Switch to doptelet from Promacata – pro
There is no literature that switching to formurlary alternatives would jeopardize the patient’s safety because Alvaiz is the same drug as Promacta, and the literature says that a switch to Doptelet is safe.
Al-Samkari H, Jiang D, Gernsheimer T, Liebman H, Lee S, Wojdyla M, Vredenburg M, Cuker A. Adults with immune thrombocytopenia who switched to avatrombopag following prior treatment with eltrombopag or romiplostim: A multicentre US study. Br J Haematol. 2022 May;197(3):359-366. doi: 10.1111/bjh.18081. Epub 2022 Feb 18. PMID: 35179784; PMCID: PMC9306832.
What data are available to support switching between thrombopoietin receptor agonists in patients with immune thrombocytopenia? https://dig.pharmacy.uic.edu/faqs/2022-2/september-2022-faqs/what-data-are-available-to-support-switching-between-thrombopoietin-receptor-agonists-in-patients-with-immune-thrombocytopenia/ Accessed 4/24/2025
Mei, H., Liu, X., Li, Y. et al. Switching from eltrombopag to hetrombopag in patients with primary immune thrombocytopenia: a post-hoc analysis of a multicenter, randomized phase III trial. Ann Hematol 103, 2273–2281 (2024). https://doi.org/10.1007/s00277-024-05826-5